MOESM3 of Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

Seremet, Teofila; Jansen, Yanina; Planken, Simon; Njimi, Hassan; Delaunoy, MĂŠlanie; El Housni, Hakim; Awada, Gil; Schwarze, Julia; Keyaerts, Marleen; Everaert, Hendrik; Lienard, Danielle; Marmol, VĂŠronique; Heimann, Pierre; Neyns, Bart

doi:10.6084/m9.figshare.9777104.v1

12967_2019_2051_MOESM3_ESM.docx (24.42 kB)

MOESM3 of Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

journal contribution

posted on 2019-09-06, 04:32 authored by Teofila Seremet, Yanina Jansen, Simon Planken, Hassan Njimi, MĂŠlanie Delaunoy, Hakim El Housni, Gil Awada, Julia Schwarze, Marleen Keyaerts, Hendrik Everaert, Danielle Lienard, VĂŠronique Marmol, Pierre Heimann, Bart Neyns

Additional file 3: Table S1. Longitudinal monitoring of patients with progressive disease exclusively in the central nervous system. Table S2. Absolute values of longitudinal monitoring of patients with >â500 copies of mutated ctDNA/ml of plasma at baseline and/or at week 3.

Funding

Kom op tegen Kanker

History

Usage metrics

Keywords

Translational research Liquid biopsy Circulating tumor DNA Monitoring Immunotherapy Metastatic melanoma BRAF/NRAS mutations monitoring

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

MOESM3 of Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

Funding

Kom op tegen Kanker

History

Usage metrics

Categories

Keywords

Licence

Exports